Prilosec OTC Brandname Defended By P&G In Response To Petition
This article was originally published in The Tan Sheet
Executive Summary
More than 90% of participants in Procter & Gamble's label comprehension studies for Prilosec OTC understood all warning statements, the firm states in Sept. 26 comments to FDA
You may also be interested in...
Mylan Says OTC, Rx Prilosec Not Bioequivalent In Study
Prilosec OTC is not bioequivalent to prescription Prilosec under the conditions of a small clinical study recently submitted to FDA by Mylan Labs, according to the firm
Mylan Says OTC, Rx Prilosec Not Bioequivalent In Study
Prilosec OTC is not bioequivalent to prescription Prilosec under the conditions of a small clinical study recently submitted to FDA by Mylan Labs, according to the firm
Mylan Says OTC, Rx Prilosec Not Bioequivalent In Study
Prilosec OTC is not bioequivalent to prescription Prilosec under the conditions of a small clinical study recently submitted to FDA by Mylan Labs, according to the firm